Investors plowed $116 million in a Series B round into Unity Biotechnology, which is focusing its early work on halting atherosclerotic disease.

The IPO raised the offer price and the number of shares sold with backing from new investors Pfizer and BB Biotech.

Allergan is buying Motus Therapeutics, a subsidiary of Rhythm Holding designed to hold its diabetic gastroparesis treatment relamorelin, under an option deal…

ProQR Therapeutics saw its stock surge on the back of data from a small clinical trial of its cystic fibrosis drug QR-010.

It has discontinued lead Phase IIb maturation inhibitor BMS-955176, which it bought from BMS, and COPD candidate losmapimod.

Biogen is aggressively pursuing neurodegenerative diseases, such as spinal muscular atrophy and Alzheimer’s disease.

Genomics Medicine Ireland has raised $40 million in a Series A round to create a genomic R&D program based in Dublin.

An IPO for Ra Pharmaceuticals has priced raising $92 million, while another for Myovant Sciences has commitments from Pfizer and BB Biotech.

Verona Pharma has secured funding for a Phase IIa trial of its PDE3/PDE4 inhibitor RPL554 in cystic fibrosis patients.